Previous close | 55.80 |
Open | 55.88 |
Bid | 55.83 x 800 |
Ask | 55.86 x 1200 |
Day's range | 55.76 - 56.04 |
52-week range | 31.45 - 60.20 |
Volume | |
Avg. volume | 2,743,158 |
Market cap | 10.109B |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -7.18 |
Earnings date | 17 May 2024 - 21 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 56.70 |
TAK vs. CTLT: Which Stock Is the Better Value Option?
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a spokesperson said on Monday. Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.